Probe position may change results in liver stiffness measurements in transient elastography

July 29, 2009

A major clinical challenge is to find the best method to evaluate and to manage the increasing numbers of patients with chronic liver disease. Liver biopsy, due to its risks and limitations, is no longer considered mandatory as the first-line indicator of liver injury, and several markers have been developed as non-invasive alternatives.

The assessment of liver fibrosis by non-invasive techniques, such as biomarkers FibroTest® (FT) and liver stiffness measurement (LSM) by Fibroscan®, is now widely performed in countries where these techniques are available and approved. It is therefore essential to identify factors associated with a variability of the results of the techniques to reduce the risk of false positives or false negatives. There are no published procedures for the most accurate position of the probe in LSM.

A research article recently published on July 21,2009 in the World Journal of Gastroenterology addresses this issue. The research team led by Professor Thierry Poynard from the Hepatology Department of the Pitié-Salpêtrière Hospital in Paris, France, found that the applicability of Fibroscan examinations may increase when the probe is placed in a more anterior position. So far, recommendations for Fibroscan examinations derive from a spot vaguely defined as the "liver biopsy zone" which is in the axillary line in the 8th to 10th intercostal space. The article further investigates possible changes in fibrosis grades due to the different probe positions. The mean LSM was significantly lower (0.5 kPa) at the anterior position versus the reference position. This difference was also clinically significant. When using the anterior position instead of the reference position, 7% of patients changed status from advanced fibrosis to non-advanced fibrosis when a cutoff of 7.1 kPa was chosen. The difference of 0.5 kPa is particularly clinically relevant in the zone of 7 kPa to 9 kPa for the risk of a false negative/positive diagnosis of advanced fibrosis; it is less relevant for the diagnosis of cirrhosis as LSM cutoffs are usually recommended at a 12.5 kPa or 14 kPa cutoff with a range to 75 kPa.

Interestingly, the estimated fibrosis scores were compared with FibroTest® and not with liver biopsy in this study. The diagnostic value of LSM and FT has been validated in the most common chronic liver diseases and FT has shown as having at least a similar prognostic value to liver biopsy (which is also an imperfect gold-standard) in patients with chronic hepatitis C and B.

Non-invasive techniques will increasingly replace liver biopsy in chronic liver disease because they are easy-to-do and well accepted by patients. This study helps to improve the understanding of possible limitations of transient elastography. Further research will be needed to define advantages and pitfalls of this technique.
-end-
Reference: Ingiliz P, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T. Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol 2009; 15(27): 3398-3404

http://www.wjgnet.com/1007-9327/15/3398.asp

Correspondence to: Dr. Patrick Ingiliz, AP-HP Hospital Group Pitié-Salpêtrière, Hepatology Department, 47-83 Hospital, Boulevard, Cedex 13, Paris 75651, France. p_ingiliz@web.de
Telephone: +49-176-24031902 Fax: +49-30-130202977

World Journal of Gastroenterology

Related Chronic Liver Disease Articles from Brightsurf:

Fatty liver disease despite a normal weight
Researchers from the University of Tsukuba found significant differences in the clinical presentation of non-obese patients with non-alcoholic fatty liver disease (NAFLD) based on their sex and body mass index.

Sobering reminder about liver disease
Alcohol's popularity and its central place in socialising in Australia obscures the dangers of excessive drinking and possible liver disease, Flinders University experts warn.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Fatty liver disease is underdiagnosed in the US
According to an analysis published in Alimentary Pharmacology & Therapeutics, nonalcoholic fatty liver disease (NAFLD) is grossly underdiagnosed in the United States.

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Lactobacillus balances gut microbiome and improves chronic-alcohol-induced liver injury
Researchers demonstrated that Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome and counter the liver-damaging effects of alcohol consumption in mice to reverse the results of chronic alcohol-induced liver injury.

Regeneration mechanism discovered in mice could provide target for drugs to combat chronic liver disease
Researchers at the University of Cambridge have uncovered a novel molecular mechanism that allows damaged adult liver cells to regenerate, paving the way for design of drugs to boost regeneration in conditions such as cirrhosis or other chronic liver diseases where regeneration is impaired.

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer
Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver disease, non-alcoholic fatty liver inflammation and liver cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg and from Zurich University and University Hospital have now shown in a publication.

The Lancet: Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated with reduced risk of mortality and liver cancer, according to a study published in The Lancet.

Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.

Read More: Chronic Liver Disease News and Chronic Liver Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.